AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1293915
Drug: Combined multidrug
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined multidrug treatment (MDT) and immunotherapy with heat killed Mycobacterium w or BCG, administered intradermally every six months.
Trial: 1293915
Drug: Multidrug treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidrug treatment (MDT) alone
Trial: 3838188
Drug: MOPP chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOPP chemotherapy plus extensive radiotherapy (mantle and paraaortic areas)
Trial: 3838188
Drug: MOPP chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOPP chemotherapy plus involved field radiotherapy
Trial: 3838188
Drug: MOPP chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOPP chemotherapy plus extensive radiotherapy
Trial: 30973337
Drug: SFSW intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SFSW intervention (Web-based training program with 11 weekly themes and associated telephone sessions)
Trial: 25220844
Drug: Tyrosine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tyrosine (300 mg/kg)
Trial: 18444444
Drug: Dronabinol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dronabinol (20 mg)
Trial: 21890886
Drug: 6% w/v
RxNorm normalized name: PROPYLENE GLYCOL 0.6 g in 100 mL OPHTHALMIC LIQUID [VISTA MEIBO TEARS Propylene Glycol 0.6% w/v Advanced Dry Eye Relief Lubricating Drops 10 ml]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% w/v hydroxyethyl starch solution (HES)
Trial: 21890886
Drug: Hartmann (crystalloid)
RxNorm normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hartmann (crystalloid) solution (HS)
Trial: 1863724
Drug: Phenylephrine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine infusion
Trial: 19695776
Drug: Internet treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet treatment group (8 weeks of online modules including relaxation training, cognitive strategies, parent operant techniques, communication strategies, and sleep and activity interventions)
Trial: 17908057
Drug: Periosteal stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periosteal stimulation therapy (PST)
Trial: 12426738
Drug: Low-dose spiral
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose spiral CT screening
Trial: 9231947
Drug: Org 10172
RxNorm normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Org 10172 (1250 anti‐Xa Units s.c. once daily)
Trial: 9231947
Drug: Heparin sodium
RxNorm normalized name: Heparin Sodium
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heparin sodium (5000 IU s.c. twice daily)
Trial: 2493376
Drug: Antibiotics plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics plus intravenous gammaglobulin (i.v. IgG)
Trial: 2493376
Drug: Antibiotics (cefataxim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics (cefataxim and amikacin)
Trial: 29132440
Drug: Immediate, intensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate, intensive periodontal treatment (n=30)
Trial: 29132440
Drug: Delayed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed treatment (n=30)
Trial: 26016052
Drug: Pharmacological therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological therapy and CPAP (Group B)
Trial: 26016052
Drug: Pharmacological therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological therapy only (Group A)
Trial: 23131570
Drug: Sea buckthorn
RxNorm normalized name: sea buckthorn
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sea buckthorn oil (SBO) extract, 4 capsules per day, each containing 500 mg, for 8 weeks
Trial: 23131570
Drug: Placebo, 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 4 capsules per day for 8 weeks
Trial: 22283033
Drug: Zinc (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc (5 mg), Iron (6.25 mg), Folic Acid (25 microg) supplementation
Trial: 22283033
Drug: Combined micronutrient
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined micronutrient supplements (Zinc, Iron, Folic Acid)
Trial: 20128376
Drug: monotherapy (amlodipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: monotherapy (amlodipine 5 mg or valsartan 80 mg)
Trial: 16401691
Drug: Citalopram (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (20 mg for three weeks, 40 mg for three weeks)
Trial: 10894590
Drug: 24 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 24 weeks of combination therapy
Trial: 10894590
Drug: 48 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 48 weeks of combination therapy
Trial: 9004394
Drug: Treatment effect
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment effect estimate under covariate omission or categorization
Trial: 27867020
Drug: PO baclofen
RxNorm normalized name: Baclofen
DrugBank: Baclofen (DB00181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PO baclofen 20 mg
Trial: 27867020
Drug: IV baclofen
RxNorm normalized name: Baclofen
DrugBank: Baclofen (DB00181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV baclofen 15 mg
Trial: 27867020
Drug: PO baclofen
RxNorm normalized name: Baclofen
DrugBank: Baclofen (DB00181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PO baclofen (10 mg, 15 mg, 20 mg)
Trial: 27867020
Drug: IV baclofen
RxNorm normalized name: Baclofen
DrugBank: Baclofen (DB00181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV baclofen (7.5 mg, 11.5 mg, 15 mg)
Trial: 23345946
Drug: Partially hydrolyzed
RxNorm normalized name: Human Skin Proteins, Partially Hydrolyzed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partially hydrolyzed guar gum (PHGG) at dosage of 5 g/d (n = 30)
Trial: 19299778
Drug: Oral 5
RxNorm normalized name: Syringe Oral 5cc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 5 mg melatonin
Trial: 14504664
Drug: Bambuterol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bambuterol (10 mg tablets twice daily)
Trial: 14504664
Drug: Terbutaline (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline (7.5 mg controlled release tablets twice daily)
Trial: 14504664
Drug: Intravenous terbutaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous terbutaline (injected intradermally)
Trial: 10490735
Drug: Pneumococcal polysaccharide
RxNorm normalized name: pneumococcal polysaccharides (23)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pneumococcal polysaccharide (Pnc PS) vaccine
Trial: 10490735
Drug: Hib-diphtheria toxoid
RxNorm normalized name: DIPHTHERIA TOXOID
DrugBank: Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (DB10584)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hib-diphtheria toxoid conjugate vaccine (PRP-D)
Trial: 31211448
Drug: BIIB054 (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIIB054 (15 or 45 mg/kg)
Trial: 13678427
Drug: Irbesartan (angiotensin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan (angiotensin II type I receptor antagonist)
Trial: 13678427
Drug: Atenolol (beta1‐adrenoceptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (beta1‐adrenoceptor blocker)
Trial: 11045833
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of antacid and anti-ulcer drugs during the last month of pregnancy by mothers
Trial: 11045833
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of antacid and anti-ulcer treatments
Trial: 1827006
Drug: 1.25 mg
RxNorm normalized name: menthol 1.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg isradipine twice daily
Trial: 1533528
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg diltiazem thrice daily
Trial: 24121915
Drug: Betamethasone (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betamethasone (12 mg)
Trial: 6691394
Drug: Hydrocortisone (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone (250 mg)
Trial: 6691394
Drug: Methylprednisolone (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (125 mg)
Trial: 26982815
Drug: Tirasemtiv (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirasemtiv (125 mg b.i.d. for one week, then escalating to a maximum tolerated dose up to 250 mg b.i.d.)
Trial: 24786192
Drug: Topical formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical formulation with high water activity
Trial: 24786192
Drug: Topical formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical formulation with urea
Trial: 24786192
Drug: Topical formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical formulation with glycerol
Trial: 24786192
Drug: Topical formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical formulation with low water activity
Trial: 21194471
Drug: High protein
RxNorm normalized name: Vital High Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High protein meal replacement (HP) providing 2.2 g protein/kg of lean body mass (LBM)/day
Trial: 21194471
Drug: Standard protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard protein meal replacement (SP) providing 1.1 g protein/kg LBM/day
Trial: 17478542
Drug: Indian HB
RxNorm normalized name: Indian frankincense
DrugBank: Indian frankincense (DB14275)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indian HB vaccine (GeneVac‐B)
Trial: 17478542
Drug: European HB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: European HB vaccine (Engerix‐B)
Trial: 2844467
Drug: S‐9780 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S‐9780 (1 mg administered intravenously)
Trial: 2844467
Drug: Perindopril (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril (8 mg administered orally)
Trial: 21177013
Drug: Intravenous cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cyclophosphamide (n = 39)
Trial: 18326602
Drug: CARB-L (lunch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CARB-L (lunch intervention)
Trial: 16549962
Drug: Lamivudine monotherapy
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lamivudine monotherapy (300 mg once daily)
Trial: 16549962
Drug: Complete therapy
RxNorm normalized name: Monistat 7 Complete Therapy Combination Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complete therapy interruption (TI group)
Trial: 7711339
Drug: Fluconazole 100
RxNorm normalized name: fluconazole 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole 100 mg
Trial: 17917321
Drug: Losartan 50
RxNorm normalized name: LOSARTAN 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 50 mg
Trial: 10619580
Drug: Candesartan cilexetil
RxNorm normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Candesartan cilexetil 8 mg vs 16 mg
Trial: 1777373
Drug: Intramuscular administration
RxNorm normalized name: Japanese Encephalitis vaccine for intramuscular administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular administration of dermatan sulphate (100 and 300 mg)
Trial: 1777373
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of dermatan sulphate (1 g)
Trial: 7028071
Drug: Inhaled beclomethasone
RxNorm normalized name: beclomethasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled beclomethasone dipropionate preceded 10 minutes earlier by inhalation of salbutamol
Trial: 7028071
Drug: Inhaled beclomethasone
RxNorm normalized name: beclomethasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled beclomethasone dipropionate followed 10 minutes later by salbutamol
Trial: 22410469
Drug: Wedge supine
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wedge supine position immediately after spinal injection (group S)
Trial: 6754416
Drug: Budesonide nasal
RxNorm normalized name: budesonide nasal
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide nasal spray (200 micrograms and 400 micrograms per day)
Trial: 28937065
Drug: Intravenous cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cyclophosphamide (i.v. CyP)
Trial: 24621999
Drug: Losartan 50
RxNorm normalized name: LOSARTAN 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 50 mg twice a day
Trial: 21355150
Drug: Acupoint-catgut-embedding therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint-catgut-embedding therapy combined with conventional western medication
Trial: 25233647
Drug: Conventional western
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional western medication
Trial: 7658972
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human erythropoietin (rHuEPO) administered at 25 U/kg/dose, i.v. route, three times weekly, adjusted according to hematimetric response.
Trial: 7658972
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human erythropoietin (rHuEPO) treatment.
Trial: 3300135
Drug: PGE2 gel,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGE2 gel, 0.5 mg (2.5 ml)
Trial: 3300135
Drug: Non-gel control
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-gel control
Trial: 25449207
Drug: Alkaline phosphatase
RxNorm normalized name: Alkaline phosphatase
DrugBank: Alkaline Phosphatase (DB05768)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alkaline phosphatase ≤143 U/l
Trial: 25449207
Drug: Bone-specific alkaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone-specific alkaline phosphatase (BSAP) <146 U/l
Trial: 25449207
Drug: Prostate-specific antigen
RxNorm normalized name: Sus scrofa prostate preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostate-specific antigen (PSA) level <10 ng/ml
Trial: 25449207
Drug: Hemoglobin >128g/l
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemoglobin >128g/l
Trial: 22759078
Drug: OZ439 (200-800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OZ439 (200-800 mg/day for 3 days as oral dispersion)
Trial: 21724705
Drug: CH-1504 (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CH-1504 (0.25 mg, 0.5 mg, or 1.0 mg once-daily oral doses)
Trial: 21724705
Drug: MTX (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTX (titrated to 20.0 mg once-weekly oral doses)
Trial: 12673721
Drug: Isoprinosine (adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoprinosine (adjuvant treatment)
Trial: 10903017
Drug: Esmolol (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol (15 mg/min) added to cold blood cardioplegia
Trial: 9021698
Drug: Autologous bone
RxNorm normalized name: Human autologous bone marrow derived osteoblastic cells
DrugBank: Human autologous bone marrow derived osteoblastic cells (DB18259)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous bone marrow transplantation (ABMT) after high dose therapy
Trial: 28985286
Drug: Organizational-support strategies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Organizational-support strategies (e.g. manager support, emails) with activity tracker
Trial: 28985286
Drug: Organizational-support strategies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Organizational-support strategies (e.g. manager support, emails) without activity tracker
Trial: 24315492
Drug: Corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid injection + thumb spica cast (CSI + TSC)
Trial: 23494116
Drug: Corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid injection (CSI)
Trial: 15807879
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone therapy for 6 months
Trial: 15994622
Drug: Triphasic oral
RxNorm normalized name: CeeNU, triphasic oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triphasic oral contraceptive (25-mug daily dose of ethinyl estradiol)
Trial: 15994622
Drug: Contraceptive vaginal
RxNorm normalized name: VCF 4% Contraceptive Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contraceptive vaginal ring (15-mug daily dose of ethinyl estradiol)
Trial: 6217028
Drug: Triphasic oral
RxNorm normalized name: CeeNU, triphasic oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triphasic oral contraceptive
Trial: 12622108
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anaesthesia (group B) using propofol and remifentanil infusions
Trial: 2423788
Drug: Indoramin 25
RxNorm normalized name: indoramin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indoramin 25 mg three times daily
Trial: 2423788
Drug: Indoramin 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indoramin 0.2 mg/kg i.v.
Trial: 30546229
Drug: Experimental A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental A group (conventional, noninvasive treatment with raj‐yoga meditation therapy and pranayama)
Trial: 30546229
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (conventional, noninvasive treatment)
Trial: 30546229
Drug: Experimental B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental B group (Raj‐yoga meditation therapy and pranayama only)
Trial: 27715335
Drug: Salmeterol/Fluticasone (SFC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol/Fluticasone (SFC) 50/500 μg twice daily
Trial: 9589819
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate 0.1% ointment
Trial: 1103916
Drug: Intramuscular administration
RxNorm normalized name: Japanese Encephalitis vaccine for intramuscular administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular administration into the vastus lateralis muscle of diazepam 10 mg
Trial: 31577085
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g intravenous vitamin C
Trial: 31577085
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg aceclofenac
Trial: 17990218
Drug: Single carbohydrate
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single carbohydrate feeding (SF) - 2.5 g carbohydrate per kg body mass, 3 hours before exercise
Trial: 9301390
Drug: Intradermal testing
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal testing
Trial: 7957157
Drug: Large contact
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Large contact material mass (3559 g)
Trial: 1297939
Drug: Midazolam 15
RxNorm normalized name: midazolam 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 15 mg once daily for seven days
Trial: 6925461
Drug: C 1821,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C 1821, administered orally for 14 days
Trial: 6925461
Drug: Placebo, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, administered orally for 14 days
Trial: 29436087
Drug: Multidirectional reach
RxNorm normalized name: beach strawberry extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidirectional reach training combined with conventional physical therapy (30 min each, 3 days a week for 4 weeks)
Trial: 29436087
Drug: Conventional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional physical therapy (30 min per day, 3 days a week for 4 weeks)
Trial: 24012203
Drug: Continuous norepinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous norepinephrine administration starting with 2 μg/kg per hour combined with 1 ml/kg per hour of Ringer's maleate solution until bladder removal, then 3 ml/kg per hour of Ringer's maleate solution (norepinephrine/low‐volume group)
Trial: 24012203
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving 6 ml/kg per hour of Ringer's maleate solution throughout surgery
Trial: 21660978
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg danoprevir solution delivered to the distal small bowel and colon via an Enterion™ capsule
Trial: 16532880
Drug: Specialty approach
RxNorm normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Specialty approach (medication restricted to smoking cessation clinics)